Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TK1 | P04183 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6471981 | 0.83 | MAPK1 (0.44) | MAPK1TK1HPGDTYMPALDH1A1 | |
| SCHEMBL28799576 | 0.80 | MAPK1 (0.41) | MAPK1TK1HPGDTYMP | |
| SCHEMBL2183944 | 0.80 | MAPK1 (0.61) | MAPK1TK1HPGDTYMPSMN1; SMN2 | |
| SCHEMBL24205457 | 0.80 | LMNA (0.32) | TK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL456976 | 0.79 | KDM4E (0.44) | MAPK1TK1HPGDTYMPALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL4194711 | 0.78 | MAPK1 (0.59) | MAPK1TK1HPGDTYMPSMN1; SMN2 | |
| SCHEMBL815121 | 0.75 | KDM3B (0.42) | HPGDALDH1A1NPSR1 | |
| SCHEMBL13615530 | 0.74 | KMT2A (0.34) | ALDH1A1 | |
| SCHEMBL10105028 | 0.74 | KMT2A (0.40) | MAPK1TK1HPGDTYMPSMN1; SMN2 | |
| SCHEMBL11723021 | 0.73 | SMN1; SMN2 (0.44) | MAPK1TK1HPGDTYMPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4182737-B1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2024-07-03 | — | — | EP | disclosed |
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2022012798-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022012799-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2022-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6D, PDE6A | MAPK1 3249/4885TK1 2551/4885HPGD 65/4885 |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | MAPK1 3072/4885TK1 2438/4885HPGD 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.